Title |
Efficacy of a Non-Hormonal Treatment, BRN-01, on Menopausal Hot Flashes
|
---|---|
Published in |
Drugs in R&D, December 2012
|
DOI | 10.2165/11640240-000000000-00000 |
Pubmed ID | |
Authors |
Jean-Claude Colau, Stéphane Vincent, Philippe Marijnen, François-André Allaert |
Abstract |
Homeopathic medicines have a place among the non-hormonal therapies for the treatment of hot flashes during the menopause. Objective: The objective of this study was to evaluate the efficacy of the non-hormonal treatment BRN-01 in reducing hot flashes in menopausal women. |
X Demographics
The data shown below were collected from the profiles of 35 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 12 | 34% |
Canada | 3 | 9% |
United Kingdom | 3 | 9% |
Cameroon | 1 | 3% |
Spain | 1 | 3% |
Netherlands | 1 | 3% |
South Africa | 1 | 3% |
Ireland | 1 | 3% |
Unknown | 12 | 34% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 30 | 86% |
Practitioners (doctors, other healthcare professionals) | 3 | 9% |
Science communicators (journalists, bloggers, editors) | 1 | 3% |
Scientists | 1 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Iran, Islamic Republic of | 1 | 3% |
Unknown | 34 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 7 | 20% |
Other | 3 | 9% |
Student > Master | 3 | 9% |
Professor | 3 | 9% |
Researcher | 3 | 9% |
Other | 3 | 9% |
Unknown | 13 | 37% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 11 | 31% |
Nursing and Health Professions | 5 | 14% |
Agricultural and Biological Sciences | 2 | 6% |
Biochemistry, Genetics and Molecular Biology | 2 | 6% |
Unknown | 15 | 43% |
Attention Score in Context
This research output has an Altmetric Attention Score of 51. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 April 2022.
All research outputs
#783,597
of 24,366,830 outputs
Outputs from Drugs in R&D
#10
of 353 outputs
Outputs of similar age
#6,091
of 288,948 outputs
Outputs of similar age from Drugs in R&D
#1
of 32 outputs
Altmetric has tracked 24,366,830 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 353 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.7. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 288,948 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 32 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.